No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
SVRA241220C2000
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-38.08%PremiumDec 20, 2024Expiry Date1.23Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.08Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Wells Fargo Initiates Savara(SVRA.US) With Buy Rating, Announces Target Price $8
Wells Fargo Initiates Coverage On Savara With Overweight Rating, Announces Price Target of $8
Savara Analyst Ratings
JMP Securities Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9
Savara Positioned for Success: Buy Rating Boosted by Strong BLA Progress and Market Potential for Molbreevi
Savara Initiates Rolling Submission Of Biologics License Application To FDA For MOLBREEVI In Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis